Home › Research › Treatments
Therapierefraktärer Status epilepticus bei Therapie mit Anti-Amyloid-AK
Neuroradiologie Scan, 2025-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Eine Möglichkeit zur Behandlung von beginnenden Alzheimer-Erkrankungen stellten Anti-Amyloid-Antikörper (AK) dar, die die Amyloidablagerungen im Gehirn reduzieren sollen. Allerdings wurden unter der Behandlung in der Bildgebung des Gehirns Auffälligkeiten beobachtet (amyloid-related imaging abnormalities, ARIA). Fazit Bei der Behandlung eines Morbus Alzheimer sollten sich Kliniker immer ins Gedächtnis rufen, dass spezifisch gegen die Alzheimer-typischen Veränderungen gerichtete Therapien mit schweren Nebenwirkungen einher gehen können, so die Autoren. Sie kommen zwar selten vor, aber werden sie nicht erkannt, kann der Verlauf fatal enden. Längsschnittstudien sollten die Veränderungen in der MRT über die Zeit untersuchen und so mögliche Hochrisikogruppen identifizieren. Publication History Article published online: 01 January 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
What this study adds
Evidence grade: Low
This report describes refractory status epilepticus during treatment with anti-amyloid antibodies, noting that therapies targeting Alzheimer-typical changes can cause serious side effects. Although these are rare, failure to recognize them can be fatal, and the authors call for longitudinal MRI studies to identify possible high-risk groups.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Therapierefraktärer Status epilepticus bei Therapie mit Anti-Amyloid-AK. (2025). Neuroradiologie Scan. https://doi.org/10.1055/a-2462-0741
Vancouver
Therapierefraktärer Status epilepticus bei Therapie mit Anti-Amyloid-AK. Neuroradiologie Scan. 2025. doi:10.1055/a-2462-0741.
BibTeX
@article{study2025-1c190b50,
title = {{Therapierefraktärer Status epilepticus bei Therapie mit Anti-Amyloid-AK}},
journal = {Neuroradiologie Scan},
year = {2025},
doi = {10.1055/a-2462-0741},
url = {https://doi.org/10.1055/a-2462-0741}
}
Built from the record alzhub holds for this paper, not looked up. This record has no authors, so the citation leaves them out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Fazit Bei der Behandlung eines Morbus Alzheimer sollten sich Kliniker immer ins Gedächtnis rufen, dass spezifisch gegen die Alzheimer-typischen Veränderungen gerichtete Therapien mit schweren Nebenwirkungen einher gehen können, so die Autoren.
- Sie kommen zwar selten vor, aber werden sie nicht erkannt, kann der Verlauf fatal enden.
- Längsschnittstudien sollten die Veränderungen in der MRT über die Zeit untersuchen und so mögliche Hochrisikogruppen identifizieren.
- Publication History Article published online: 01 January 2025 © 2025.
- Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
Why it matters
This report describes refractory status epilepticus during treatment with anti-amyloid antibodies, noting that therapies targeting Alzheimer-typical changes can cause serious side effects. Although these are rare, failure to recognize them can be fatal, and the authors call for longitudinal MRI studies to identify possible high-risk groups.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 25/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record and institution's track record, so those were left out: it earned 23 of the 93 points we could judge it on, which is 25 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Neuroradiologie Scan) |
| Journal's citation record | 0 / 4 | Neuroradiologie Scan: journal h-index 4 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 1 / 2 | Not in PubMed, but has a DOI |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 23 / 93 | Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 23 of the 93 points we could judge it on is 25 out of 100. |
| Total | 25 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.